The Evolving Role of Diet and Gut Microbiome in Inflammatory Bowel Disease

One misconception in clinical practice is the immediate restriction of dietary fiber post-diagnosis. Sarbagili notes that many patients limit their fiber intake despite evidence suggesting its beneficial role in microbiota composition and metabolite production. While fiber restriction may be appropriate for patients with strictures, it generally should not be the standard approach. Hansen emphasized that dietary advice must reflect the disease stage: higher fiber intake is encouraged before disease onset, low-fiber diets may be suitable during active episodes of Crohn’s disease, and fiber can typically be reintroduced during remission.

Large-scale studies of treatment-naïve IBD patients show decreased microbial diversity, a hallmark of IBD. Hansen stated that the comparison group matters significantly when interpreting microbial signals, as differences are often clearer between IBD patients and symptomatic controls rather than healthy individuals. Common findings include an increase in oral-associated microbes and a decrease in strictly anaerobic organisms, which supports the so-called oxygen hypothesis. The challenge remains in discerning whether inflammation alters the microbiome or if the microbiome influences inflammation.

Both experts highlight ongoing debates about the microbiome's role in IBD pathogenesis, with Hansen suggesting Crohn's disease may be connected to microbiome alterations. However, proving causality is complex, especially since inflammation can change gut conditions. Interventions like fecal microbiota transplantation (FMT) have shown varying efficacy in ulcerative colitis, indicating the microbiome's potential relevance.

Population-based research indicates that a healthy dietary pattern—high in fruits, vegetables, legumes, nuts, seeds, and fiber—may be linked to lower IBD risk. Hansen identified ultra-processed foods as a concerning factor, while Sarbagili recommended a focus on overall diet quality rather than strict avoidance of certain foods.

Exclusive enteral nutrition (EEN) is considered the most evidence-based dietary strategy for Crohn’s disease, inducing shifts in gut microbiota composition. Though the current dietary strategy evidence for ulcerative colitis is less robust, strategies such as reducing red meat and increasing fiber intake may support pharmacological treatments and improve clinical outcomes.

Looking to the future, microbiome-based therapies, including probiotics, have yet to significantly impact IBD management due to challenges in strain selection. Both Hansen and Sarbagili foresee a more integrated therapeutic approach combining diet, microbiome strategies, and medications.

Understanding the interplay between diet and the gut microbiome at various stages of IBD is crucial for developing personalized management strategies. While many questions remain, integrating these approaches with existing therapies offers a promising pathway for more effective treatment.